201 related articles for article (PubMed ID: 16156885)
1. Clinical benefit of interventions driven by therapeutic drug monitoring.
Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
[TBL] [Abstract][Full Text] [Related]
2. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
[TBL] [Abstract][Full Text] [Related]
3. The use of therapeutic drug monitoring in the management of protease inhibitor-related toxicity.
Forsyth SF; French PD; Macfarlane E; Gibbons SE; Miller RF
Int J STD AIDS; 2005 Feb; 16(2):139-41. PubMed ID: 15807942
[TBL] [Abstract][Full Text] [Related]
4. [Treatment strategies and surveillance of chronic HIV infection in adults].
Joly V; Yeni P
Rev Prat; 1999 Oct; 49(16):1773-80. PubMed ID: 10578608
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of antiretroviral agents.
Bean P; Patnaik M; Graziano FM; Aziz DC
Am Clin Lab; 2000 May; 19(4):20-2. PubMed ID: 10947316
[TBL] [Abstract][Full Text] [Related]
6. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
Antinori A; Cozzi-Lepri A; Ammassari A; Trotta MP; Nauwelaers D; Hoetelmans R; Murri R; Melzi S; Narciso P; Nasta P; Zaccarelli M; Santopadre P; Vecchiet J; Izzo CM; Maonforte Ad;
Antivir Ther; 2004 Apr; 9(2):291-6. PubMed ID: 15134192
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of antiretroviral agents scenario.
Moltó J; Clotet B
J HIV Ther; 2004 Nov; 9(4):75-8. PubMed ID: 15731738
[TBL] [Abstract][Full Text] [Related]
8. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.
Clevenbergh P; Mouly S; Sellier P; Badsi E; Cervoni J; Vincent V; Trout H; Bergmann JF
Curr HIV Res; 2004 Oct; 2(4):309-21. PubMed ID: 15544452
[TBL] [Abstract][Full Text] [Related]
9. Managing issues related to antiretroviral therapy.
Lesho EP; Gey DC
Am Fam Physician; 2003 Aug; 68(4):675-86. PubMed ID: 12952384
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.
Alexander CS; Asselin JJ; Ting LS; Montaner JS; Hogg RS; Yip B; O'Shaughnessy MV; Harrigan PR
J Infect Dis; 2003 Aug; 188(4):541-8. PubMed ID: 12898441
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of antiretroviral therapy.
Di Perri G; Sinicco A; Audagnotto S; Gobbi F; Canta F; Marrone R; Bonora S
New Microbiol; 2004 Apr; 27(2 Suppl 1):131-4. PubMed ID: 15646076
[TBL] [Abstract][Full Text] [Related]
12. [The value of plasma antiretroviral drug monitoring in the management of HIV infected patients].
Tréluyer JM
Ann Med Interne (Paris); 2000 Jun; 151(4):291-6. PubMed ID: 10922957
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV drug update.
Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
[TBL] [Abstract][Full Text] [Related]
14. Guidance offered in drug combination choices.
AIDS Alert; 1997 Dec; 12(12):135-7. PubMed ID: 11364831
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
Boffito M; Acosta E; Burger D; Fletcher CV; Flexner C; Garaffo R; Gatti G; Kurowski M; Perno CF; Peytavin G; Regazzi M; Back D
Antivir Ther; 2005; 10(4):469-77. PubMed ID: 16038472
[TBL] [Abstract][Full Text] [Related]
16. Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care.
de Maat MM; Huitema AD; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Ther Drug Monit; 2003 Jun; 25(3):367-73. PubMed ID: 12766566
[TBL] [Abstract][Full Text] [Related]
17. The intracellular pharmacology of antiretroviral protease inhibitors.
Ford J; Khoo SH; Back DJ
J Antimicrob Chemother; 2004 Dec; 54(6):982-90. PubMed ID: 15537695
[TBL] [Abstract][Full Text] [Related]
18. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.
Boffito M; Acosta E; Burger D; Fletcher CV; Flexner C; Garaffo R; Gatti G; Kurowski M; Perno CF; Peytavin G; Regazzi M; Back D
Antivir Ther; 2005; 10(3):375-92. PubMed ID: 15918329
[TBL] [Abstract][Full Text] [Related]
19. Drug level monitoring: the next advance in diagnostics.
Proj Inf Perspect; 2001 Aug; (33):6-8. PubMed ID: 11838409
[TBL] [Abstract][Full Text] [Related]
20. Are nonnucleoside analogue-based regimens better than protease inhibitor-based regimens for nonadherent HIV-infected patients?
Knobel H
Clin Infect Dis; 2005 Jan; 40(1):164-6. PubMed ID: 15614707
[No Abstract] [Full Text] [Related]
[Next] [New Search]
